RxDoctor Payments Data

Aric Clegg

Ophthalmology · Florence, SCNPI 1588125694

Payments from drug & device makers

$1,481in general payments, 2019–2025

Across 36 payments — averaging $41.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$537
  • Alcon$536
  • Harrow Eye, LLC$124
  • Rxsight Inc$121
  • AbbVie$64
  • Glaukos Corporation$61
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$1,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,481 in reported general payments places this provider in the 40th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$212,394
Medicare patients
433
Services billed
2,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate287$116,428
LumiganBimatoprost67$28,029
VyzultaLatanoprostene Bunod77$24,193
CombiganBrimonidine Tartrate/Timolol58$21,532
RestasisCyclosporine22$19,009
Prednisolone Acetate306$15,711
Latanoprost2,454$14,316
SimbrinzaBrinzolamide/Brimonidine Tart50$12,848
XiidraLifitegrast13$12,813
Brimonidine Tartrate1,001$12,812
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol98$12,049
Brinzolamide55$11,714
RocklatanNetarsudil Mesylat/Latanoprost23$11,308
Dorzolamide Hcl566$10,933
Timolol Maleate964$9,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$64$68,570147 claims
AlconSimbrinza$536$12,84850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →